NCT02890719

Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.

• Status: Withdrawn
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Fundacion Clinic per a la Recerca Biomédica · Academic / Other
• Sex: All
• Age: 18 Years – 78 Years
• Healthy volunteers: Not accepted

Summary

Pilot, single center, open-label study to evaluate the efficacy and tolerability of Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant recipients with hepatitis C recurrence.

Conditions

• Liver Transplantation
• Hepatitis C

Interventions

Type	Name	Description
DRUG	Grazoprevir 100 mg/day	Grazoprevir 100 mg/ day 12 weeks
DRUG	Elbasvir 50 mg/d	Elbasvir 50 mg/day 12 weeks
DRUG	Grazoprevir 100 mg/day	Grazoprevir 100 mg/day 16 weeks
DRUG	Elbasvir 50 mg/day	Elbasvir 50 mg/d 16 weeks
DRUG	Ribavirin 1200 mg/day	Ribavirin 1200 mg/day 16 weeks

Timeline

• Start date: 2016-08-03
• Primary completion: 2017-06-01
• Completion: 2017-06-01
• First posted: 2016-09-07
• Last updated: 2025-06-22